TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20829341

Group type: EXPERIMENTAL
Intervention: Protective ventilation strategy (PV group, n=50): FIO2 0.5, tidal volume 6 mL/kg, positive end-expiratory pressure 5 cm H2O, pressure-controlled ventilation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional ventilation strategy (CV group, n=50): FIO2 1.0, tidal volume 10 mL/kg, zero end-expiratory pressure, volume-controlled ventilation
Number of subjects: 100
Study: 18577309

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Dexamethasone 0.1%/tobramycin 0.3% (DM/T)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Artificial tears (baseline)
Number of subjects: 306
Study: 16941973

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Auricular point pressing therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Medication (saitazan, 10 mg once daily)
Number of subjects: 150
Study: 14641306

Group type: EXPERIMENTAL
Intervention: Celecoxib, 200 mg orally twice per day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo, administered orally with the same dosing schedule as celecoxib
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 11344213

Group type: EXPERIMENTAL
Intervention: Glucosamine infusion (4 micromol/dL.min) from 90-240 min (n=6)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glucosamine infusion (4 micromol/dL.min) from 0-300 min (n=6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (placebo; n=6)
Number of subjects: 18
Study: 10178659

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 19394

Group type: COMPARATOR
Intervention: control group
Number of subjects: 19394
Study: 8157786

Group type: EXPERIMENTAL
Intervention: Thymopentin (Timunox), 50 mg, thrice-weekly subcutaneous injections
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 2893314

Group type: COMPARATOR
Intervention: Low-dose intraventricular bethanechol (0.35 mg/d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moderate-dose intraventricular bethanechol (up to 1.75 mg/d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-dose intraventricular bethanechol (1.75 mg/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study: 29429800

Group type: EXPERIMENTAL
Intervention: Intensity‐modulated radiotherapy (IMRT) with concurrent platinum‐based chemotherapy (CCRT group, n = 27)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by radical surgery with or without adjuvant treatment (NACT group, n = 39)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Radical surgery with or without adjuvant treatment (RH group, n = 25)
Number of subjects: 91
Study: 28320368

Group type: EXPERIMENTAL
Intervention: Decision aid (6-min videoclip explaining diagnosis and surgery options)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Regular information only (Control)
Number of subjects: 80
Study: 25474194

Group type: EXPERIMENTAL
Intervention: Reconstructive surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal faces
Number of subjects: 120

Group type: COMPARATOR
Intervention: Facial lesions
Number of subjects: 120
Study: 23343386

Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity (three 50-minute sessions/week over 10 weeks)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Chronic Pain Self-Management Program (2.5-hours per week over 6 weeks)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Health Guidance (1.5-hour individualised dialogue)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Chronic Pain Self-Management Program
Number of subjects: 138

Group type: COMPARATOR
Intervention: Health Guidance
Number of subjects: 138
Study: 21640689

Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18975316

Group type: EXPERIMENTAL
Intervention: Genetic testing for DM2 in patients diagnosed with FM
Number of subjects: 63

Group type: COMPARATOR
Intervention: Asymptomatic controls
Number of subjects: 63
Study: 16816554

Group type: EXPERIMENTAL
Intervention: Apricitabine 400 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Apricitabine 800 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Apricitabine 1200 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Apricitabine 1600 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12601207

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intraarterial angiography (control)
Number of subjects: 34
Study: 10567286

Group type: EXPERIMENTAL
Intervention: Pulmonary autograft
Number of subjects: 47

Group type: COMPARATOR
Intervention: Aortic homograft
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 8916239

Group type: EXPERIMENTAL
Intervention: Program with employment specialist
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group with no specialized vocational services
Number of subjects: 122
Study: 1919633

Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN gamma) at 10, 50, or 100 micrograms/m2 plus tumor necrosis factor-alfa (TNF alpha) at 10, 50, or 100 micrograms/m2 every other day for 20 days (10 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of 100 micrograms/m2 IFN gamma and 50 micrograms/m2 TNF alpha every other day (maximally tolerated dose)
Number of subjects: 0
Study: 6925851

Group type: EXPERIMENTAL
Intervention: Educational program with high indirect interventions
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Emphasis on negative consequences of uncontrolled hypertension
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Additional meetings and emphasis on patient responsibility (combined)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Educational program (overall)
Number of subjects: 160
Study: 31486777

Group type: EXPERIMENTAL
Intervention: High-frequency MST (100 Hz)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Medium-frequency MST (60 or 50 Hz)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Low-frequency MST (25 Hz)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: MST (overall)
Number of subjects: 86
Study: 31441409

Group type: EXPERIMENTAL
Intervention: Shenfu group (received 60 mL Shenfu injection infusion for 7 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shenfu group
Number of subjects: 50
Study: 28585750

Group type: EXPERIMENTAL
Intervention: Liberal fluid therapy (30 mL kg‐1 h‐1 infusion of Ringer's lactate solution)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Restricted fluid therapy (10 mL kg‐1 h‐1 infusion of Ringer's lactate solution)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Liberal fluid therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Restricted fluid therapy
Number of subjects: 150
Study: 26645521

Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS2) 10 g/d for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23178539

Group type: EXPERIMENTAL
Intervention: Noxious thermal stimulation (heat pain 46-47°C/cold pain 2-3°C) 3 days/week for 8 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Innocuous thermal stimulation (heat 40-41°C/cold 23-24°C) 3 days/week for 8 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Noxious thermal stimulation
Number of subjects: 34
Study: 21465247

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion (0.3 g kg(‐1) body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18077465

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 33
Study: 16503887

Group type: EXPERIMENTAL
Intervention: 2% ketanserin ointment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unmedicated vehicle (placebo)
Number of subjects: 12
Study: 12776029

Group type: EXPERIMENTAL
Intervention: PEG with the introducer method (Group I)
Number of subjects: 58

Group type: COMPARATOR
Intervention: PEG with the pull method (Group II)
Number of subjects: 58
Study: 10884197

Group type: EXPERIMENTAL
Intervention: Cup with cluster holes for adjunctive screw fixation (n = 30)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cup without holes (n = 34)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 9231316

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 1524744

Group type: EXPERIMENTAL
Intervention: Sealed resin composite restoration (CompS/C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultra-conservative sealed amalgam restorations (AGS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional unsealed amalgam restorations (AGU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sealed amalgam restorations (AGS)
Number of subjects: 0
Study: 6344379

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 27

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 27
Study: 3532242

Group type: EXPERIMENTAL
Intervention: Psychological training of stress management, relaxation, and self-control techniques for 13 type A post-MI patients over a 4-8 week inpatient rehabilitation programme.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group KG (A) - 23 type A post-MI patients who did not receive psychological training.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group KG (B) - 20 type A smoker counselling clients who did not receive psychological training.
Number of subjects: 91
Study: 28315922

Group type: EXPERIMENTAL
Intervention: Combined femoral-obturator-sciatic nerve block (FOS Group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Posterior lumbar plexus block and sciatic nerve block (PLPS Group)
Number of subjects: 0
Study: 27474357

Group type: EXPERIMENTAL
Intervention: Sumatriptan iontophoretic transdermal system (TDS) for 4 hours
Number of subjects: 37
Study: 23059481

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with 2 permanent and 2 releasable sutures (R group)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard trabeculectomy (S group)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 175
Study: 22434537

Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 21122658

Group type: EXPERIMENTAL
Intervention: Directly measured low-density lipoprotein cholesterol (D-LDL-C)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Calculated low-density lipoprotein cholesterol (C-LDL-C)
Number of subjects: 81
Study: 18640794

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (20% concentration)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30% concentration)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (40% concentration)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (100% oxygen)
Number of subjects: 32
Study: 16417773

Group type: EXPERIMENTAL
Intervention: Penyanqing Capsule (PYQC), 3 times a day, 4 capsules each time, for 2 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Fuyankang tablets (FYKT), 3 times a day, 6 tablets each time, for 2 months
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Penyanqing Capsule (PYQC)
Number of subjects: 82
Study: 12847648

Group type: EXPERIMENTAL
Intervention: Lösferron (ferrous gluconate, Lilly Pharma, Hamburg) - 0.5 l
Number of subjects: 52

Group type: COMPARATOR
Intervention: No oral contrast agent
Number of subjects: 52
Study: 10561318

Group type: EXPERIMENTAL
Intervention: CD8(+) tumor-infiltrating lymphocytes (TILs) plus low-dose recombinant interleukin-2 (rIL-2)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo cell infusion plus low-dose recombinant interleukin-2 (rIL-2)
Number of subjects: 178
Study: 8759178

Group type: EXPERIMENTAL
Intervention: 0.90 IU/kg/week (D2)
Number of subjects: 97

Group type: COMPARATOR
Intervention: 0.45 IU/kg/week (D1)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study: 1762973

Group type: EXPERIMENTAL
Intervention: Relaxing music (preference of seven types)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (60-cycle hum)
Number of subjects: 15
Study: 7110301

Group type: EXPERIMENTAL
Intervention: Stepped-care treatment
Number of subjects: 7825

Group type: COMPARATOR
Intervention: Referred care
Number of subjects: 7825
Study: 30121121

Group type: EXPERIMENTAL
Intervention: Parental involvement
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Parental presence
Number of subjects: 111

Group type: COMPARATOR
Intervention: Parental absence
Number of subjects: 111
Study: 29655624

Group type: EXPERIMENTAL
Intervention: Routine immunizations (DTwP-HepB-Hib, oral polio, pneumococcal conjugate 7 vaccines)
Number of subjects: 212
Study: 27189657

Group type: EXPERIMENTAL
Intervention: 0.02 mL/kg dose of 10% fluorescein sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.01 mL/kg dose of 10% fluorescein sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pCLE
Number of subjects: 0
Study: 25322766

Group type: COMPARATOR
Intervention: Regular NHGDoc decision support modules
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Regular NHGDoc decision support modules plus an additional module on heart failure
Number of subjects: 120
Study: 22708649

Group type: EXPERIMENTAL
Intervention: TBV 600 mg BID monotherapy for 4 weeks followed by combination therapy with PIFN (pre-dosing arm)
Number of subjects: 42

Group type: COMPARATOR
Intervention: TBV administered concurrently with PIFN (standard dosing arm)
Number of subjects: 42
Study: 20063435

Group type: EXPERIMENTAL
Intervention: S90049 (60 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 30
Study: 17387129

Group type: EXPERIMENTAL
Intervention: Atorvastatin plus 60 mg of torcetrapib daily
Number of subjects: 1188

Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 1188
Study: 16139703

Group type: EXPERIMENTAL
Intervention: Tourniquet inflated on straight leg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tourniquet inflated on maximally flexed knee
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tourniquet deflation
Number of subjects: 100
Study: 11694947

Group type: EXPERIMENTAL
Intervention: Recombinant urate oxidase
Number of subjects: 183

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 183
Study: 9415234

Group type: EXPERIMENTAL
Intervention: Topical 5-aminolaevulinic acid photodynamic therapy
Number of subjects: 22
Study: 7894919

Group type: COMPARATOR
Intervention: Regional nerve block (RNB) with stellate ganglion block and suprascapular nerve block by 1% xylocaine 10 ml
Number of subjects: 150

Group type: COMPARATOR
Intervention: Electroacupuncture (EAP) with local acupoints: Chien‐Yu, Chien‐Ching, Chien‐Nei‐Ling, Ah‐Shih Hsueh
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of EAP + RNB
Number of subjects: 150
Study: 2440351

Group type: EXPERIMENTAL
Intervention: Meperidine (mean dose 4.3 +/- 0.2 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Morphine (0.6 +/- 0.02 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl (7 +/- 0.4 micrograms/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil (1.3 +/- 0.1 microgram/kg)
Number of subjects: 60
Study: 30453076

Group type: EXPERIMENTAL
Intervention: eHealth Familias Unidas Primary Care
Number of subjects: 456

Group type: COMPARATOR
Intervention: Prevention as usual
Number of subjects: 456
Study: 28205185

Group type: EXPERIMENTAL
Intervention: OPERA dietary supplement (alpha-lipoic acid, Boswellia Serrata, methylsulfonylmethane, and bromelain)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: OPERA dietary supplement
Number of subjects: 25
Study: 25812128

Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Test (PASAT) administered to patients with MS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paced Auditory Serial Addition Test (PASAT) administered to normal controls
Number of subjects: 100
Study: 23669304

Group type: EXPERIMENTAL
Intervention: Alginate-antacid (Gaviscon Double Action Liquid)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Antacid (Antagel)
Number of subjects: 16
Study: 21884858

Group type: EXPERIMENTAL
Intervention: Emergency Medical Services (EMS) transport
Number of subjects: 263

Group type: COMPARATOR
Intervention: Self-presenting patients
Number of subjects: 263
Study: 19114704

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg every 2 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus irinotecan at progression
Number of subjects: 48
Study: 16955187

Group type: EXPERIMENTAL
Intervention: Oral inosiplex (50 mg/kg/day in five divided doses for 12 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15113819

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Calcium or placebo (control)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis with additional studies
Number of subjects: 1237
Study: 11720426

Group type: EXPERIMENTAL
Intervention: Accelerated chemotherapy with EVI and GM-CSF support (Arm B)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Standard chemotherapy with EVI (Arm A)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Accelerated chemotherapy with EVI and oral antibiotics (Arm C)
Number of subjects: 233
Study: 9219909

Group type: EXPERIMENTAL
Intervention: Fish oil treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 26
Study: 8238379

Group type: EXPERIMENTAL
Intervention: FK‐453 (100 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: FK‐453 (200 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: FK‐453
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3312331

Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate 0.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polidocanol 0.25%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparsal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study: 28887752

Group type: EXPERIMENTAL
Intervention: IV acetaminophen 15 mg/kg/dose
Number of subjects: 400

Group type: COMPARATOR
Intervention: PO acetaminophen 15 mg/kg/dose
Number of subjects: 400
Study: 27265058

Group type: EXPERIMENTAL
Intervention: Text prediction functions
Number of subjects: 52

Group type: COMPARATOR
Intervention: No text prediction functions (Control)
Number of subjects: 52
Study: 25675169

Group type: EXPERIMENTAL
Intervention: Transconjunctival local anesthesia with 2% lidocaine gel
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transcutaneous local anesthesia without topical anesthetic
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transconjunctival injection
Number of subjects: 120
Study: 22305809

Group type: EXPERIMENTAL
Intervention: Probucol (1000 mg orally before angioplasty and 500 mg twice daily for 3 days after intervention)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (no probucol treatment)
Number of subjects: 204
Study: 21967862

Group type: EXPERIMENTAL
Intervention: Team Check‐up Tool (TCT) administered monthly
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Team Check‐up Tool (TCT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CLABSI rate, Team Functioning Survey (TFS), Practice Environment Scale (PES) from the Nursing Work Index
Number of subjects: 46
Study: 18807007

Group type: EXPERIMENTAL
Intervention: Balanced 6% HES 130/0.42 plus a balanced crystalloid solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non‐balanced HES in saline plus saline solution
Number of subjects: 50
Study: 16539815

Group type: EXPERIMENTAL
Intervention: Phlogenzym (PE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diclofenac (DC)
Number of subjects: 90
Study: 14607210

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: B-type natriuretic peptide testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ximelagatran plus aspirin
Number of subjects: 0
Study: 10653825

Group type: EXPERIMENTAL
Intervention: (192)Ir
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 7645364

Group type: EXPERIMENTAL
Intervention: Hormonal response to electrolyte changes and water loss in patients with heat exhaustion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol levels in patients with heat exhaustion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasopressin (ADH) levels in patients with heat exhaustion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTH concentration in patients with heat exhaustion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACTH concentrations in patients with heat exhaustion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GH concentration in patients with heat exhaustion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aldosterone concentration in patients with heat exhaustion
Number of subjects: 0
Study: 2518864

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Cimetidine (800 mg)
Number of subjects: 274
Study: 782159

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31291710

Group type: EXPERIMENTAL
Intervention: Vaccination 2 weeks before chemotherapy (Arm A)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Vaccination on the first day of chemotherapy (Arm B)
Number of subjects: 92
Study: 31044546

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 5000
Study: 27910086

Group type: EXPERIMENTAL
Intervention: Transfusion at a higher haemoglobin threshold of 90 g/l
Number of subjects: 998

Group type: COMPARATOR
Intervention: Transfusion at a lower haemoglobin threshold of 70 g/l
Number of subjects: 998